Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 496

1.

Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.

Awad MM, Leonardi GC, Kravets S, Dahlberg SE, Drilon A, Noonan SA, Camidge DR, Ou SI, Costa DB, Gadgeel SM, Steuer CE, Forde PM, Zhu VW, Fukuda Y, Clark JW, Jänne PA, Mok T, Sholl LM, Heist RS.

Lung Cancer. 2019 Jul;133:96-102. doi: 10.1016/j.lungcan.2019.05.011. Epub 2019 May 11.

PMID:
31200835
2.

Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial.

Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, Yeap BY, Drapek LC, Ly L, Baglini CV, Blaszkowsky LS, Ferrone CR, Parikh AR, Weekes CD, Nipp RD, Kwak EL, Allen JN, Corcoran RB, Ting DT, Faris JE, Zhu AX, Goyal L, Berger DL, Qadan M, Lillemoe KD, Talele N, Jain RK, DeLaney TF, Duda DG, Boucher Y, Fernández-Del Castillo C, Hong TS.

JAMA Oncol. 2019 May 30. doi: 10.1001/jamaoncol.2019.0892. [Epub ahead of print]

PMID:
31145418
3.

Pencil Beam Scanning Proton Beam Chemoradiation Therapy With 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility Study.

Wo JY, Plastaras JP, Metz JM, Jiang W, Yeap BY, Drapek LC, Adams J, Baglini C, Ryan DP, Murphy JE, Parikh AR, Allen JN, Clark JW, Blaszkowsky LS, DeLaney TF, Ben-Josef E, Hong TS.

Int J Radiat Oncol Biol Phys. 2019 May 22. pii: S0360-3016(19)30747-3. doi: 10.1016/j.ijrobp.2019.04.040. [Epub ahead of print]

PMID:
31128146
4.

Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.

Parikh AR, He Y, Hong TS, Corcoran RB, Clark JW, Ryan DP, Zou L, Ting DT, Catenacci DV, Chao J, Fakih M, Klempner SJ, Ross JS, Frampton GM, Miller VA, Ali SM, Schrock AB.

Oncologist. 2019 Apr 30. pii: theoncologist.2019-0034. doi: 10.1634/theoncologist.2019-0034. [Epub ahead of print]

PMID:
31040255
5.

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.

Shaw AT, Riely GJ, Bang YJ, Kim DW, Camidge DR, Solomon BJ, Varella-Garcia M, Iafrate AJ, Shapiro GI, Usari T, Wang SC, Wilner KD, Clark JW, Ou SI.

Ann Oncol. 2019 Apr 13. pii: mdz131. doi: 10.1093/annonc/mdz131. [Epub ahead of print]

PMID:
30980071
6.

FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial.

Cleary JM, Horick NK, McCleary NJ, Abrams TA, Yurgelun MB, Azzoli CG, Rubinson DA, Brooks GA, Chan JA, Blaszkowsky LS, Clark JW, Goyal L, Meyerhardt JA, Ng K, Schrag D, Savarese DMF, Graham C, Fitzpatrick B, Gibb KA, Boucher Y, Duda DG, Jain RK, Fuchs CS, Enzinger PC.

Cancer. 2019 Mar 26. doi: 10.1002/cncr.32029. [Epub ahead of print]

PMID:
30913304
7.

High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy.

Mitra D, Horick NK, Brackett DG, Mouw KW, Hornick JL, Ferrone S, Hong TS, Mamon H, Clark JW, Parikh AR, Allen JN, Ryan DP, Ting DT, Deshpande V, Wo JY.

Oncologist. 2019 Jun;24(6):e275-e283. doi: 10.1634/theoncologist.2018-0794. Epub 2019 Feb 12.

PMID:
30755500
8.

Sex differences in mouse models of fear inhibition: Fear extinction, safety learning, and fear-safety discrimination.

Clark JW, Drummond SPA, Hoyer D, Jacobson LH.

Br J Pharmacol. 2019 Feb 2. doi: 10.1111/bph.14600. [Epub ahead of print]

PMID:
30710446
9.

Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival.

Sanford NN, Pursley J, Noe B, Yeap BY, Goyal L, Clark JW, Allen JN, Blaszkowsky LS, Ryan DP, Ferrone CR, Tanabe KK, Qadan M, Crane CH, Koay EJ, Eyler C, DeLaney TF, Zhu AX, Wo JY, Grassberger C, Hong TS.

Int J Radiat Oncol Biol Phys. 2019 Jan 23. pii: S0360-3016(19)30158-0. doi: 10.1016/j.ijrobp.2019.01.076. [Epub ahead of print]

PMID:
30684667
10.

Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy.

Hong TS, Grassberger C, Yeap BY, Jiang W, Wo JY, Goyal L, Clark JW, Crane CH, Koay EJ, Dima S, Eyler CE, Popescu I, DeLaney TF, Zhu AX, Duda DG.

NPJ Precis Oncol. 2018 Oct 18;2:22. doi: 10.1038/s41698-018-0065-y. eCollection 2018.

11.

Enrichment of HER2 Amplification in Brain Metastases from Primary Gastrointestinal Malignancies.

Mitra D, Clark JW, Shih HA, Oh KS, Brastianos PK, Wo JY, Strickland MR, Curry WT, Parikh AR, Corcoran RB, Ryan DP, Iafrate AJ, Borger DR, Lennerz JK, Hong TS.

Oncologist. 2019 Feb;24(2):193-201. doi: 10.1634/theoncologist.2018-0152. Epub 2018 Oct 29.

PMID:
30373904
12.

Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.

Chu JN, Choi J, Ostvar S, Torchia JA, Reynolds KL, Tramontano A, Gainor JF, Chung DC, Clark JW, Hur C.

Cancer. 2019 Jan 15;125(2):278-289. doi: 10.1002/cncr.31795. Epub 2018 Oct 21.

PMID:
30343509
13.

Case 32-2018: A 36-Year-Old Pregnant Woman with Newly Diagnosed Adenocarcinoma.

Murphy JE, Shampain K, Riley LE, Clark JW, Basnet KM.

N Engl J Med. 2018 Oct 18;379(16):1562-1570. doi: 10.1056/NEJMcpc1712230. No abstract available.

PMID:
30332577
14.

Are Staging Computed Tomography (CT) Scans of the Chest Necessary in Pancreatic Adenocarcinoma?

Mehtsun WT, Chipidza FE, Fernández-Del Castillo C, Hemingway K, Fong ZV, Chang DC, Pandharipande P, Clark JW, Allen J, Hong TS, Wo JY, Warshaw AL, Lillemoe KD, Ferrone CR.

Ann Surg Oncol. 2018 Dec;25(13):3936-3942. doi: 10.1245/s10434-018-6764-3. Epub 2018 Oct 1.

PMID:
30276641
15.

Reply to Hedges et al.: Accurate timetrees do indeed require accurate calibrations.

Morris JL, Puttick MN, Clark JW, Edwards D, Kenrick P, Pressel S, Wellman CH, Yang Z, Schneider H, Donoghue PCJ.

Proc Natl Acad Sci U S A. 2018 Oct 9;115(41):E9512-E9513. doi: 10.1073/pnas.1812816115. Epub 2018 Sep 28. No abstract available.

16.

A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma.

Goyal L, Zheng H, Abrams TA, Miksad R, Bullock AJ, Allen JN, Yurgelun MB, Clark JW, Kambadakone A, Muzikansky A, Knowles M, Galway A, Afflitto AJ, Dinicola CF, Regan E, Hato T, Mamessier E, Shigeta K, Jain RK, Duda DG, Zhu AX.

Clin Cancer Res. 2019 Jan 1;25(1):80-89. doi: 10.1158/1078-0432.CCR-18-0847. Epub 2018 Sep 6.

17.

Evolution of metazoan morphological disparity.

Deline B, Greenwood JM, Clark JW, Puttick MN, Peterson KJ, Donoghue PCJ.

Proc Natl Acad Sci U S A. 2018 Sep 18;115(38):E8909-E8918. doi: 10.1073/pnas.1810575115. Epub 2018 Sep 4.

18.

Integrated genomic and fossil evidence illuminates life's early evolution and eukaryote origin.

Betts HC, Puttick MN, Clark JW, Williams TA, Donoghue PCJ, Pisani D.

Nat Ecol Evol. 2018 Oct;2(10):1556-1562. doi: 10.1038/s41559-018-0644-x. Epub 2018 Aug 20.

19.

Whole-Genome Duplication and Plant Macroevolution.

Clark JW, Donoghue PCJ.

Trends Plant Sci. 2018 Oct;23(10):933-945. doi: 10.1016/j.tplants.2018.07.006. Epub 2018 Aug 16. Review.

PMID:
30122372
20.

Liver reirradiation for patients with hepatocellular carcinoma and liver metastasis.

McDuff SGR, Remillard KA, Zheng H, Raldow AC, Wo JY, Eyler CE, Drapek LC, Goyal L, Blaszkowsky LS, Clark JW, Allen JN, Parikh AR, Ryan DP, Ferrone CR, Tanabe KK, Wolfgang JA, Zhu AX, Hong TS.

Pract Radiat Oncol. 2018 Nov - Dec;8(6):414-421. doi: 10.1016/j.prro.2018.04.012. Epub 2018 Apr 26.

PMID:
29937235
21.

Differential Association Between Circulating Lymphocyte Populations With Outcome After Radiation Therapy in Subtypes of Liver Cancer.

Grassberger C, Hong TS, Hato T, Yeap BY, Wo JY, Tracy M, Bortfeld T, Wolfgang JA, Eyler CE, Goyal L, Clark JW, Crane CH, Koay EJ, Cobbold M, DeLaney TF, Jain RK, Zhu AX, Duda DG.

Int J Radiat Oncol Biol Phys. 2018 Aug 1;101(5):1222-1225. doi: 10.1016/j.ijrobp.2018.04.026. Epub 2018 Apr 17.

PMID:
29859792
22.

Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.

Murphy JE, Wo JY, Ryan DP, Jiang W, Yeap BY, Drapek LC, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Faris JE, Zhu AX, Goyal L, Lillemoe KD, DeLaney TF, Fernández-Del Castillo C, Ferrone CR, Hong TS.

JAMA Oncol. 2018 Jul 1;4(7):963-969. doi: 10.1001/jamaoncol.2018.0329.

23.

Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis.

Kamran SC, Clark JW, Zheng H, Borger DR, Blaszkowsky LS, Allen JN, Kwak EL, Wo JY, Parikh AR, Nipp RD, Murphy JE, Goyal L, Zhu AX, Iafrate AJ, Corcoran RB, Ryan DP, Hong TS.

Cancer Med. 2018 May 17. doi: 10.1002/cam4.1558. [Epub ahead of print]

24.

Recent progress in systemic treatment for lung cancer.

Clark JW, Longo DL.

Curr Opin Pulm Med. 2018 Jul;24(4):355-366. doi: 10.1097/MCP.0000000000000493. Review.

PMID:
29697418
25.

Tivantinib for advanced hepatocellular carcinoma: is MET still a viable target?

Weekes CD, Clark JW, Zhu AX.

Lancet Oncol. 2018 May;19(5):591-592. doi: 10.1016/S1470-2045(18)30249-3. Epub 2018 Apr 3. No abstract available.

PMID:
29625880
26.

The timescale of early land plant evolution.

Morris JL, Puttick MN, Clark JW, Edwards D, Kenrick P, Pressel S, Wellman CH, Yang Z, Schneider H, Donoghue PCJ.

Proc Natl Acad Sci U S A. 2018 Mar 6;115(10):E2274-E2283. doi: 10.1073/pnas.1719588115. Epub 2018 Feb 20.

27.

Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAFV600E Colorectal Cancer.

Hazar-Rethinam M, Kleyman M, Han GC, Liu D, Ahronian LG, Shahzade HA, Chen L, Parikh AR, Allen JN, Clark JW, Kwak EL, Faris JE, Murphy JE, Hong TS, Van Seventer EE, Nadres B, Hong CB, Gurski JM Jr, Jessop NA, Dias-Santagata D, Iafrate AJ, Van Allen EM, Corcoran RB.

Cancer Discov. 2018 Apr;8(4):417-427. doi: 10.1158/2159-8290.CD-17-1227. Epub 2018 Feb 5.

28.

Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.

Michelakos T, Pergolini I, Castillo CF, Honselmann KC, Cai L, Deshpande V, Wo JY, Ryan DP, Allen JN, Blaszkowsky LS, Clark JW, Murphy JE, Nipp RD, Parikh A, Qadan M, Warshaw AL, Hong TS, Lillemoe KD, Ferrone CR.

Ann Surg. 2019 Apr;269(4):733-740. doi: 10.1097/SLA.0000000000002600.

PMID:
29227344
29.

Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype.

Hong TS, Wo JY, Borger DR, Yeap BY, McDonnell EI, Willers H, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Tanguturi S, Goyal L, Murphy JE, Wolfgang JA, Drapek LC, Arellano RS, Mamon HJ, Mullen JT, Tanabe KK, Ferrone CR, Ryan DP, Iafrate AJ, DeLaney TF, Zhu AX.

J Natl Cancer Inst. 2017 Sep 1;109(9). doi: 10.1093/jnci/djx031.

PMID:
28954285
30.

Targeting CXCR4-dependent immunosuppressive Ly6Clow monocytes improves antiangiogenic therapy in colorectal cancer.

Jung K, Heishi T, Incio J, Huang Y, Beech EY, Pinter M, Ho WW, Kawaguchi K, Rahbari NN, Chung E, Kim JK, Clark JW, Willett CG, Yun SH, Luster AD, Padera TP, Jain RK, Fukumura D.

Proc Natl Acad Sci U S A. 2017 Sep 26;114(39):10455-10460. doi: 10.1073/pnas.1710754114. Epub 2017 Sep 12.

31.

Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases.

Miller CL, Taylor MS, Qadan M, Deshpande V, Worthington S, Smalley R, Collura C, Ryan DP, Allen JN, Blaszkowsky LS, Clark JW, Murphy JE, Parikh AR, Berger D, Tanabe KK, Lillemoe KD, Ferrone CR.

J Gastrointest Surg. 2017 Nov;21(11):1831-1840. doi: 10.1007/s11605-017-3557-0. Epub 2017 Sep 7.

PMID:
28884391
32.

Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529.

Mitra D, Hong TS, Horick N, Rose B, Drapek LN, Blaszkowsky LS, Allen JN, Kwak EL, Murphy JE, Clark JW, Ryan DP, Cusack JC, Bordeianou LG, Berger DL, Wo JY.

Adv Radiat Oncol. 2017 Feb 6;2(2):110-117. doi: 10.1016/j.adro.2017.01.009. eCollection 2017 Apr-Jun.

33.

Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy.

Jung K, Heishi T, Khan OF, Kowalski PS, Incio J, Rahbari NN, Chung E, Clark JW, Willett CG, Luster AD, Yun SH, Langer R, Anderson DG, Padera TP, Jain RK, Fukumura D.

J Clin Invest. 2017 Aug 1;127(8):3039-3051. doi: 10.1172/JCI93182. Epub 2017 Jul 10.

34.

Constraining the timing of whole genome duplication in plant evolutionary history.

Clark JW, Donoghue PCJ.

Proc Biol Sci. 2017 Jul 12;284(1858). pii: 20170912. doi: 10.1098/rspb.2017.0912.

35.

Standard fractionation external beam radiotherapy with and without intraoperative radiotherapy for locally recurrent rectal cancer: the role of local therapy in patients with a high competing risk of death from distant disease.

Kishan AU, Voog JC, Wiseman J, Cook RR, Ancukiewicz M, Lee P, Ryan DP, Clark JW, Berger DL, Cusack JC, Wo JY, Hong TS.

Br J Radiol. 2017 Aug;90(1076):20170134. doi: 10.1259/bjr.20170134. Epub 2017 Jun 14.

36.

Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma.

Liu H, Naxerova K, Pinter M, Incio J, Lee H, Shigeta K, Ho WW, Crain JA, Jacobson A, Michelakos T, Dias-Santos D, Zanconato A, Hong TS, Clark JW, Murphy JE, Ryan DP, Deshpande V, Lillemoe KD, Fernandez-Del Castillo C, Downes M, Evans RM, Michaelson J, Ferrone CR, Boucher Y, Jain RK.

Clin Cancer Res. 2017 Oct 1;23(19):5959-5969. doi: 10.1158/1078-0432.CCR-17-0256. Epub 2017 Jun 9.

37.

Irradiation of anatomically defined pelvic subsites and acute hematologic toxicity in anal cancer patients undergoing chemoradiation.

Rose B, Mitra D, Hong TS, Jee KW, Niemierko A, Drapek LN, Blaszkowsky LS, Allen JN, Murphy JE, Clark JW, Ryan DP, Wo JY.

Pract Radiat Oncol. 2017 Sep - Oct;7(5):e291-e297. doi: 10.1016/j.prro.2017.03.008. Epub 2017 Mar 23.

PMID:
28462895
38.

Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer.

Wo JY, Niemierko A, Ryan DP, Blaszkowsky LS, Clark JW, Kwak EL, Lillemoe KD, Drapek LN, Zhu AX, Allen JN, Faris JE, Murphy JE, Nipp R, Fernandez-Del Castillo C, Ferrone CR, Hong TS.

Am J Clin Oncol. 2018 Jul;41(7):656-661. doi: 10.1097/COC.0000000000000349.

PMID:
28134673
39.

Limits to Precision Cancer Medicine.

Clark JW, Chabner BA.

N Engl J Med. 2017 Jan 5;376(1):96. doi: 10.1056/NEJMc1613563. No abstract available.

PMID:
28052223
40.

Predictors of Early Mortality After Surgical Resection of Pancreatic Adenocarcinoma in the Era of Neoadjuvant Treatment.

Nipp RD, Zanconato A, Zheng H, Ferrone CR, Lillemoe KD, Wo JY, Hong TS, Clark JW, Ryan DP, Fernández-Del Castillo C.

Pancreas. 2017 Feb;46(2):183-189. doi: 10.1097/MPA.0000000000000731.

PMID:
27846142
41.

Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma.

Keane FK, Wo JY, Ferrone CR, Clark JW, Blaszkowsky LS, Allen JN, Kwak EL, Ryan DP, Lillemoe KD, Fernandez-Del Castillo C, Hong TS.

Am J Clin Oncol. 2018 Jun;41(6):607-612. doi: 10.1097/COC.0000000000000336.

PMID:
27740973
42.

Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases.

Rahbari NN, Kedrin D, Incio J, Liu H, Ho WW, Nia HT, Edrich CM, Jung K, Daubriac J, Chen I, Heishi T, Martin JD, Huang Y, Maimon N, Reissfelder C, Weitz J, Boucher Y, Clark JW, Grodzinsky AJ, Duda DG, Jain RK, Fukumura D.

Sci Transl Med. 2016 Oct 12;8(360):360ra135.

43.

Effects of Mental Health and Neuroscience Evidence on Juror Perceptions of a Criminal Defendant: the Moderating Role of Political Orientation.

Mowle EN, Edens JF, Clark JW, Sörman K.

Behav Sci Law. 2016 Nov;34(6):726-741. doi: 10.1002/bsl.2251. Epub 2016 Sep 13.

PMID:
27620269
44.

Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.

Heist RS, Sequist LV, Borger D, Gainor JF, Arellano RS, Le LP, Dias-Santagata D, Clark JW, Engelman JA, Shaw AT, Iafrate AJ.

J Thorac Oncol. 2016 Aug;11(8):1242-1245. doi: 10.1016/j.jtho.2016.06.013. Epub 2016 Jun 22.

45.

One American Perspective on the Rights of Accused: An Initial Survey of Miranda Rights in a Broader Context.

Rogers R, Sharf AJ, Clark JW 3rd, Drogin EY, Winningham DB, Williams MM.

Behav Sci Law. 2016 Jul;34(4):477-94. doi: 10.1002/bsl.2240. Epub 2016 May 23.

PMID:
27213849
46.

A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.

Indolfi L, Ligorio M, Ting DT, Xega K, Tzafriri AR, Bersani F, Aceto N, Thapar V, Fuchs BC, Deshpande V, Baker AB, Ferrone CR, Haber DA, Langer R, Clark JW, Edelman ER.

Biomaterials. 2016 Jul;93:71-82. doi: 10.1016/j.biomaterials.2016.03.044. Epub 2016 Mar 31.

47.

A protein and mRNA expression-based classification of gastric cancer.

Setia N, Agoston AT, Han HS, Mullen JT, Duda DG, Clark JW, Deshpande V, Mino-Kenudson M, Srivastava A, Lennerz JK, Hong TS, Kwak EL, Lauwers GY.

Mod Pathol. 2016 Jul;29(7):772-84. doi: 10.1038/modpathol.2016.55. Epub 2016 Apr 1.

48.

"A Psychopath by Any Other Name?": Juror Perceptions of the DSM-5 "Limited Prosocial Emotions" Specifier.

Edens JF, Mowle EN, Clark JW, Magyar MS.

J Pers Disord. 2017 Feb;31(1):90-109. doi: 10.1521/pedi_2016_30_239. Epub 2016 Mar 9.

PMID:
26959961
49.

Boldness and its relation to psychopathic personality: Prototypicality analyses among forensic mental health, criminal justice, and layperson raters.

Sörman K, Edens JF, Smith ST, Clark JW, Kristiansson M, Svensson O.

Law Hum Behav. 2016 Jun;40(3):337-49. doi: 10.1037/lhb0000176. Epub 2016 Feb 4.

PMID:
26844911
50.

The impact of neoadjuvant therapy for gastroesophageal adenocarcinoma on postoperative morbidity and mortality.

Fuentes E, Ahmad R, Hong TS, Clark JW, Kwak EL, Rattner DW, Mullen JT.

J Surg Oncol. 2016 Apr;113(5):560-4. doi: 10.1002/jso.24179. Epub 2016 Jan 21.

PMID:
26792144

Supplemental Content

Loading ...
Support Center